Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the year-ago period. The growth was primarily driven by $11 million in net sales of TONMYA, its recently approved treatment for fibromyalgia. TONMYA recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills surging 207%. These figures underscore the drug’s rapid adoption since its launch.
The company highlighted that TONMYA currently has coverage for approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to about 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. This broad reimbursement access is critical for patient uptake and reflects the company’s efforts to secure payer support for the novel therapy.
Beyond commercial progress, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments highlight the company’s commitment to addressing high unmet medical needs in central nervous system (CNS) and immunology.
Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability as the company scales TONMYA and progresses its pipeline.
The strong revenue performance and pipeline progress are pivotal for Tonix as it establishes itself as a commercial-stage biotechnology company. TONMYA, which is the first new treatment for fibromyalgia in more than 15 years, represents a significant opportunity in a market with limited therapeutic options. The drug’s rapid prescription growth and expanding coverage suggest strong market acceptance, which could translate into sustained revenue growth.
Tonix’s CNS portfolio also includes Zembrace SymTouch and Tosymra for acute migraine, along with TNX-2900 for Prader-Willi syndrome, which is Phase 2 ready. In immunology, the company is developing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. These programs diversify the company’s pipeline and mitigate reliance on a single product.
The announcement underscores the importance of TONMYA’s commercial launch and the potential of the company’s research efforts. For investors, the revenue growth and pipeline milestones are positive indicators of the company’s trajectory. As Tonix continues to execute on its commercial and clinical strategies, it aims to solidify its position in the biotechnology sector.
For more details, the full press release is available at https://ibn.fm/6Yytj. Additional updates can be found in the company’s newsroom at https://ibn.fm/TNXP.
